Tag - OpREGAN

By Len Zehr BioTime (NYSE:MKT, TASE:BTX) has multiple data milestones scheduled this year in its two lead regenerative medicine programs: OpRegen in dry AMD and Renevia in facial aesthetics. “We believe we are one of...